![John R. Jaskowiak](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John R. Jaskowiak
Directeur des opérations chez Angiocrine Bioscience, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Paul W. Finnegan | M | 63 |
Angiocrine Bioscience, Inc.
![]() Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
Jeff Jonas | M | 71 |
Angiocrine Bioscience, Inc.
![]() Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
David Parkinson | M | 73 |
Angiocrine Bioscience, Inc.
![]() Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
Jeffrey L. Port | M | - |
Angiocrine Bioscience, Inc.
![]() Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
Marc Cohen | M | - |
Angiocrine Bioscience, Inc.
![]() Angiocrine Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company based on its novel and proprietary e-cel® platform. The company is based in San Diego, CA. The company is developing multiple e-cel therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system, immune diseases that attack vessels and tissues, and ischemic diseases involving soft tissue, central nervous system, and the heart. The CEO of the company is Paul W. Finnegan. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 5 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- John R. Jaskowiak
- Réseau Personnel